Ernexa Therapeutics (ERNAW) Income towards Parent Company (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Income towards Parent Company data on file, last reported at -$5.5 million in Q1 2026.

• Quarterly Income towards Parent Company rose 32.87% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.4 million (down 640.38% YoY) and the FY2025 annual result came in at -$14.1 million, down 82947.06% from the prior year.
• Income towards Parent Company fell to -$5.5 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $38.8 million in Q4 2024 to a low of -$26.6 million in Q3 2024.
• A 5-year average of -$2.4 million and a median of -$5.5 million in 2026 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 730.54% in 2024, down 375.84% in 2024.
• Tracing ERNAW's Income towards Parent Company over 5 years: stood at $20.0 million in 2022, then sank by 130.73% to -$6.2 million in 2023, then soared by 730.54% to $38.8 million in 2024, then plunged by 103.87% to -$1.5 million in 2025, then sank by 266.58% to -$5.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$5.5 million (Q1 2026), -$1.5 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.